It is an analogue of ZSTK474.

Miltefosine inhibits PI3K/Akt activity with ED50 of 17.2 μM and 8.1 μM in carcinoma cell lines A431 and HeLa, first oral drug for Visceral leishmaniasis, effective against both promastigotes and amastigotes.

Dactolisib is an orally bioavailable imidazoquinoline targeting the phosphatidylinositol 3 kinase (PI3K) and the mammalian target of rapamycin (mTOR), with potential antineoplastic activity.

Pictilisib is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold).

Buparlisib is an orally bioavailable specific oral inhibitor of PI3K family of lipid kinases with potential antineoplastic activity.

PI-103 is a dual-kinase inhibitor with anti-cancer properties. It has a role as a PI3K inhibitor, a mTOR inhibitor and an antineoplastic agent.

NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor.

TGX-221 is a p110β-specific inhibitor.